Ticker > Company >

Aspira Pathlab&Diagn share price

Aspira Pathlab & Diagnostics Ltd.

BSE: 540788 SECTOR: Hospital & Healthcare Services  15.09 K   22   1

62.00
-2.34 (-3.64%)
BSE: 29 Oct 04:01 PM

Price Summary

Today's High

₹ 66.24

Today's Low

₹ 62

52 Week High

₹ 106.78

52 Week Low

₹ 49.05

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

63.82 Cr.

Enterprise Value

63.51 Cr.

No. of Shares

1.03 Cr.

P/E

24.95

P/B

5.03

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  12.32

CASH

1.38 Cr.

DEBT

1.08 Cr.

Promoter Holding

18.39 %

EPS (TTM)

₹  2.49

Sales Growth

-8.66%

ROE

-23.34 %

ROCE

-18.49%

Profit Growth

-2912.63 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-8.66%
3 Year-4.59%
5 Year11.57%

Profit Growth

1 Year-2912.63%
3 Year-224.61%
5 Year8.22%

ROE%

1 Year-23.34%
3 Year6.07%
5 Year-10.66%

ROCE %

1 Year-18.49%
3 Year8.52%
5 Year4.15%

Debt/Equity

0.1062

Price to Cash Flow

60.6

Interest Cover Ratio

-6.2673

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 18.39 0.00
Jun 2025 18.39 0.00
Mar 2025 18.39 0.00
Dec 2024 18.55 0.00
Sep 2024 18.55 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 0.443200000000004 days.
  • Company has a healthy liquidity position with current ratio of 2.1028.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 33.3611750646209.

 Limitations

  • The company has shown a poor profit growth of -224.611586995109% for the Past 3 years.
  • The company has shown a poor revenue growth of -4.5932079733682% for the Past 3 years.
  • Company has a poor ROE of 6.07409432237643% over the past 3 years.
  • Company has low Interest coverage ratio of -6.2673.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 4.64 6.18 5.41 5.78 5.25
Total Expenditure 4.29 4.82 4.64 4.72 4.43
Operating Profit 0.35 1.36 0.77 1.05 0.82
Other Income 0.09 0.08 0.09 0.13 0.11
Interest 0.08 0.08 0.09 0.09 0.09
Depreciation 0.38 0.36 0.39 0.37 0.37
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.02 0.99 0.38 0.72 0.47
Tax 0 0 0 0 0
Profit After Tax -0.02 0.99 0.38 0.72 0.47
Adjusted EPS (Rs) -0.02 0.96 0.37 0.7 0.46

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 8.42 15.21 19.54 14.46 13.2
Total Expenditure 10.24 11.69 13.23 12.86 14.39
Operating Profit -1.83 3.51 6.32 1.59 -1.19
Other Income 0.29 0.2 0.15 0.32 0.42
Interest 1.01 0.89 0.37 0.42 0.37
Depreciation 1.66 1.44 1.64 1.59 1.54
Exceptional Items 0 0 0 0 0
Profit Before Tax -4.21 1.38 4.46 -0.09 -2.67
Tax 0.03 0 0 0 0
Net Profit -4.24 1.38 4.46 -0.09 -2.67
Adjusted EPS (Rs.) -4.56 1.34 4.33 -0.09 -2.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.29 10.29 10.29 10.29 10.29
Total Reserves -5.49 -1.98 2.5 2.46 -0.15
Borrowings 4.55 0.77 0.86 0.96 1.08
Other N/C liabilities 0.86 0.68 2.7 2.04 1.42
Current liabilities 5.12 2.01 1.79 1.58 2.07
Total Liabilities 14.34 11.78 18.14 17.34 14.71
Assets
Net Block 8.7 7.75 9.57 8.01 6.79
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.1 0.14 1.42 3.48 3.57
Other N/C Assets 2.25 0 0 0 0
Current Assets 3.29 3.88 7.14 5.86 4.36
Total Assets 14.34 11.78 18.14 17.34 14.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -4.21 1.38 4.46 -0.09 -2.67
Adjustment 2.4 2.36 2.4 1.8 1.77
Changes in Assets & Liabilities -0.03 1.93 -4.83 -1.73 1.96
Tax Paid -0.03 0 0 0 0
Operating Cash Flow -1.87 5.67 2.03 -0.01 1.05
Investing Cash Flow 0.24 -0.09 -0.51 0.16 0.14
Financing Cash Flow 1.27 -2.17 -1.35 -0.94 -0.95
Net Cash Flow -0.35 3.41 0.17 -0.79 0.24

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 18.55 18.55 18.39 18.39 18.39
arvind karsandas bhanusha... 8.60 8.60 8.60 8.60 8.60
deepali arvind bhanushali... 8.60 8.60 8.60 8.60 8.60
paresh bhanji bhanushali 0.58 0.58 0.43 0.43 0.43
raj arvind bhanushali 0.76 0.76 0.76 0.76 0.76
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 81.45 81.45 81.61 81.61 81.61
aditya agrawal 7.39 7.39 7.39 7.39 7.39
amit modi 2.92 2.92 2.92 2.92 2.92
amit modi huf 2.82 2.82 2.82 2.82 2.82
devji deyat nanda 1.31 1.31 1.31 1.31 1.31
dhvani vinod bhanushali 2.91 2.91 2.91 2.91 2.91
jay arvind bhanushali 2.22 2.22 2.22 2.26 2.26
llp - 0.20 0.25 0.25 0.96
manas modi 3.36 3.36 3.36 3.36 3.36
manoj ramsisaria 1.99 1.99 1.99 1.99 1.99
nikunj velji mange 2.14 2.14 2.14 2.14 2.14
pankaj jashwant shah 4.86 4.86 4.86 4.86 4.86
pooja rajesh bhanushali 3.60 3.60 3.60 3.60 3.60
puspahas agrawal 2.80 2.80 2.80 2.80 2.80
rajesh premji bhanushali 5.49 5.52 5.52 5.52 5.52
ram awtar ramsisaria 2.40 2.40 2.40 2.40 2.40
rinku vinod bhanushali 8.10 8.10 8.10 8.10 8.10
saakshi gupta 1.40 1.40 1.40 1.40 1.40
shraddha jagdish bhanusha... 1.46 1.46 1.46 1.46 1.46
shradha ramsisaria 1.47 1.47 1.47 1.47 1.47
vinod pradhan bhanushali 5.01 5.01 5.01 5.01 5.01
vinod pradhan bhanushali ... 2.91 2.91 2.91 2.91 2.91

Annual Reports

Title Link
Title Link
Annual Report 2022
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Aspira Pathlab&Diagn - Quaterly Results 12 Aug, 5:22 PM Aspira Pathlab&Diagn - Quaterly Results 12 Aug, 5:22 PM Aspira Pathlab&Diagn - Quaterly Results 16 May, 8:09 PM Aspira Pathlab&Diagn - Quaterly Results 16 May, 8:09 PM Aspira Pathlab & Diagnostics informs about contact details of RTA 22 Apr, 4:58 PM Aspira Pathlab&Diagn - Quaterly Results 7 Feb, 5:31 PM Aspira Pathlab&Diagn - Quaterly Results 7 Feb, 5:31 PM Aspira Pathlab & Diagnostics informs about newspaper publication 4 Sep, 3:49 PM Aspira Pathlab & Diagnostics informs about book closure 24 Aug, 2:26 PM Aspira Pathlab & Diagnostics informs about AGM 24 Aug, 2:17 PM Aspira Pathlab&Diagn - Quaterly Results 13 Aug, 6:26 PM Aspira Pathlab & Diagnostics informs about disclosure 9 Apr, 2:12 PM Aspira Pathlab & Diagnostics informs about disclosure 19 Mar, 12:25 PM Aspira Pathlab & Diagnostics informs about disclosure 16 Mar, 12:57 PM Aspira Pathlab & Diagnostics opens new Diagnostics Center in Mumbai 2 Mar, 12:33 PM Aspira Pathlab & Diagnostics informs about disclosure 2 Mar, 12:13 PM Aspira Pathlab&Diagn - Quaterly Results 13 Feb, 5:02 PM Aspira Pathlab&Diagn - Quaterly Results 13 Feb, 5:02 PM Aspira Pathlab & Diagnostics informs about closure of trading window 28 Dec, 5:01 PM Aspira Pathlab & Diagnostics informs about newspaper publication 13 Nov, 12:58 PM Aspira Pathlab & Diagnostics informs about change in directorate 12 Aug, 2:39 PM Aspira Pathlab & Diagnostics informs about resignation of CS cum CO 24 Jun, 3:36 PM Aspira Pathlab & Diagnostics informs about compliance certificate 10 Apr, 5:31 PM Aspira Pathlab & Diagnostics informs about postal ballot voting results 25 Mar, 10:23 AM Aspira Pathlab & Diagnostics informs about press release 22 Feb, 12:16 PM Aspira Pathlab & Diagnostics informs about disclosure 2 Jan, 3:39 PM Aspira Pathlab & Diagnostics informs about scrutinizer’s report and voting results 12 Sep, 4:36 PM Aspira Pathlab & Diagnostics informs about scrutinizer's report 12 Sep, 4:24 PM Aspira Pathlab & Diagnostics informs about newspaper publication 19 Aug, 4:04 PM Aspira Pathlab & Diagnostics informs about disclosure 4 Jul, 4:23 PM Aspira Pathlab & Diagnostic informs about postal ballot notice 7 Jun, 2:54 PM Aspira Pathlab & Diagnostics informs about certificate 16 Oct, 12:40 PM Aspira Pathlab & Diagnostics informs about resignation of CS cum CO 24 Sep, 10:17 AM Aspira Pathlab & Diagnostics informs about AGM notice with annual report 30 Aug, 3:30 PM Aspira Pathlab & Diagnostics informs about board meeting 6 Feb, 10:22 AM

Aspira Pathlab&Diagn Stock Price Analysis and Quick Research Report. Is Aspira Pathlab&Diagn an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aspira Pathlab&Diagn. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aspira Pathlab&Diagn has a PE ratio of 24.9476903267343 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aspira Pathlab&Diagn has ROA of -16.6745% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aspira Pathlab&Diagn has a Current ratio of 2.1028.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aspira Pathlab&Diagn has a ROE of -23.3445%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aspira Pathlab&Diagn has a Debt to Equity ratio of 0.1062 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aspira Pathlab&Diagn has reported revenue growth of -8.6602% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aspira Pathlab&Diagn for the current financial year is -8.99211656279109%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aspira Pathlab&Diagn is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aspira Pathlab&Diagn is Rs 2.4852. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aspira Pathlab&Diagn in Ticker for free. Also, one can get the intrinsic value of Aspira Pathlab&Diagn by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aspira Pathlab&Diagn FAQs

Q1. What is Aspira Pathlab&Diagn share price today?
Ans: The current share price of Aspira Pathlab&Diagn is Rs 62.

Q2. What is the market capitalisation of Aspira Pathlab&Diagn?
Ans: Aspira Pathlab&Diagn has a market capitalisation of Rs 63.8166 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aspira Pathlab&Diagn?
Ans: The PE ratio of Aspira Pathlab&Diagn is 24.9476903267343 and the P/B ratio of Aspira Pathlab&Diagn is 5.03046677863512, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aspira Pathlab&Diagn share?
Ans: The 52-week high share price of Aspira Pathlab&Diagn is Rs 106.78, and the 52-week low share price of Aspira Pathlab&Diagn is Rs 49.05.

Q5. Does Aspira Pathlab&Diagn pay dividends?
Ans: Currently, Aspira Pathlab&Diagn does not pay dividends. Dividend yield of Aspira Pathlab&Diagn is around 0%.

Q6. What are the face value and book value of Aspira Pathlab&Diagn shares?
Ans: The face value of Aspira Pathlab&Diagn shares is Rs 10, while the book value per share of Aspira Pathlab&Diagn is around Rs 12.3249. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aspira Pathlab&Diagn?
Ans: Aspira Pathlab&Diagn has a total debt of Rs 1.0772 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aspira Pathlab&Diagn?
Ans: The ROE of Aspira Pathlab&Diagn is -23.3445% and ROCE of Aspira Pathlab&Diagn is -18.4858%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aspira Pathlab&Diagn a good buy for the long term?
Ans: The Aspira Pathlab&Diagn long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aspira Pathlab&Diagn undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aspira Pathlab&Diagn appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aspira Pathlab&Diagn’s financials?
Ans: You can review Aspira Pathlab&Diagn’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aspira Pathlab&Diagn
X